You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

40-GEP

Showing 1 - 25 of 8,967
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Regional Nodal Basins and Gene Expression Profiling in Primary

Not yet recruiting
  • Cutaneous Squamous Cell Carcinoma of the Head and Neck
  • Ultrasound
  • 40-GEP
  • (no location specified)
Jul 12, 2023

Acromegaly, GEP-NET Trial in Worldwide (Debio 4126, Sandostatin LAR, Somatuline ATG)

Recruiting
  • Acromegaly
  • GEP-NET
  • Debio 4126
  • +2 more
  • Copenaghen, Denmark
  • +34 more
Jan 27, 2023

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Active, not recruiting
  • Gastroenteropancreatic Neuroendocrine Tumor
    • El Palmar, Murcia, Spain
    • +15 more
    Feb 16, 2022

    Effectiveness and Outcomes Associated With Lutathera Treatment

    Active, not recruiting
    • Gastroenteropancreatic Neuroendocrine Tumor
    • Alessandria, Italy
    • +17 more
    May 4, 2022

    Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma Trial in Indianapolis (sentinel lymph node

    Recruiting
    • Squamous Cell Carcinoma
    • +2 more
    • sentinel lymph node biopsy (SLNB)
    • Indianapolis, Indiana
      Indiana University Melvin & Bren Simon Cancer Center
    Nov 15, 2022

    Neuroendocrine Tumors,Gastroenteropancreatic Trial in Taipei (Cabozantinib, Lanreotide)

    Not yet recruiting
    • Neuroendocrine Tumors,Gastroenteropancreatic
    • Taipei, Taiwan
      National Taiwan University Hospital
    Sep 9, 2021

    Lung Neuroendocrine Tumor, GEP Neuroendocrine Tumor Trial in Naples (Cabozantinib and Temozolomide)

    Recruiting
    • Lung Neuroendocrine Neoplasm
    • GEP Neuroendocrine Tumor
    • Cabozantinib and Temozolomide
    • Naples, Campania, Italy
      National Cancer Institute of Naples
    Oct 12, 2021

    Multiple Myeloma Trial in Little Rock (Pomalidomide)

    Completed
    Has Results
    • Multiple Myeloma
    • Little Rock, Arkansas
      University of Arkansas for Medical Sciences, Myeloma Institute f
    Mar 30, 2021

    Vulva Cancer, Vulva Tumor, Squamous Cell Cancer Trial (Pembrolizumab)

    Not yet recruiting
    • Vulva Cancer
    • +2 more
    • (no location specified)
    Mar 7, 2023

    Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin,

    Completed
    Has Results
    • Well-differentiated Non-functional NET of Thoracic Origin
    • +3 more
    • Duarte, California
    • +34 more
    Mar 16, 2021

    Chromogranin A as Blood Marker in Cancer Patients

    Completed
    • Gastric Neoplasms
    • +3 more
    • BRAHMS CgA II KRYPTOR
    • Palo Alto, California
    • +3 more
    Dec 19, 2022

    Neuroendocrine Carcinoma Trial in France (FOLFOXIRI Protocol, Cisplatin injection)

    Recruiting
    • Neuroendocrine Carcinoma
    • FOLFOXIRI Protocol
    • Cisplatin injection
    • Caen, France
    • +5 more
    Apr 13, 2021

    Neuroendocrine Tumor, Gastroenteropancreatic Trial in Milano (Surgery)

    Active, not recruiting
    • Neuroendocrine Tumor
    • Gastroenteropancreatic
    • Surgery
    • Milano, Italy
      San Raffaele Hospital IRCCS
    May 5, 2022

    Advanced NSCLC Trial in Worldwide (Pembrolizumab, Favezelimab, Lenvatinib)

    Active, not recruiting
    • Advanced Non-Small Cell Lung Cancer
    • Pembrolizumab
    • +3 more
    • Tempe, Arizona
    • +80 more
    Aug 23, 2022

    Gastroenteropancreatic Neuroendocrine Tumours

    Recruiting
    • Gastroenteropancreatic Neuroendocrine Tumor
    • 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
    • Milano, Italy
      Irccs San Raffaele
    Nov 24, 2023

    Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

    Not yet recruiting
    • Digestive System Neuroendocrine Tumor G1
    • +5 more
    • Tumor Debulking
    • +5 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Aug 23, 2023

    Neuroendocrine Tumors Trial in Seoul (Lanreotide autogel)

    Recruiting
    • Neuroendocrine Tumors
    • Lanreotide autogel
    • Seoul, Korea, Republic of
      Changhoon Yoo
    Jul 18, 2022

    GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, 64Cu-Dotatate)

    Enrolling by invitation
    • GEP-NET
    • +3 more
    • Copenhagen, Denmark
      Rigshospitalet
    Jan 24, 2023

    Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

    Recruiting
    • Neuroendocrine Tumors
    • Peptide Receptor Radionuclide Therapy
    • Rotterdam, South Holland, Netherlands
      Erasmus MC
    May 19, 2023

    Gastroenteropancreatic Neuroendocrine Tumors Trial in Marseille ([68Ga]-DOTANOC PET/CT)

    Completed
    • Gastroenteropancreatic Neuroendocrine Tumors
    • [68Ga]-DOTANOC PET/CT
    • Marseille, France
      AP-HM
    Oct 12, 2022

    Donor Derived Cell Free DNA and Histopathology in Kidney

    Not yet recruiting
    • Transplant;Failure,Kidney
    • +2 more
      • (no location specified)
      Apr 11, 2023

      Gastro-Enteropancreatic Neuroendocrine Tumor Trial in Austria, Denmark, United States (Satoreotide trizoxetan 5-20µg,

      Completed
      Has Results
      • Gastro-Enteropancreatic Neuroendocrine Tumor
      • Satoreotide trizoxetan 5-20μg
      • Satoreotide trizoxetan 30-45μg
      • Los Angeles, California
      • +4 more
      Jan 8, 2021

      Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Trial in Worldwide (Lutetium [177Lu]

      Recruiting
      • Gastroenteropancreatic Neuroendocrine Tumors
      • +2 more
      • Lutetium [177Lu] oxodotreotide/dotatate
      • Iowa City, Iowa
      • +16 more
      Apr 6, 2022

      Neuroendocrine Tumors Trial in New York (177Lu-DOTA-EB-TATE, Amino Acid Solution)

      Recruiting
      • Neuroendocrine Tumors
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Jul 22, 2022

      Lutathera® in Somatostatin Receptor Positive

      Recruiting
      • Somatostatin Receptor-positive GEP-NET
      • Lutathera
      • Seongnam Si, Gyeonggi Do, Korea, Republic of
      • +4 more
      Jun 29, 2022